EFRON GIL enters PURPLE BIOTECH LTD. with 15.75M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 3/31/2026ACC: 0001213900-26-036868
Officer· Chief Executive Officer
Since Mar 2026
15.75M
Baseline shares
100% direct
15.75M
Direct ownership
1 position
18.75M
Derivative underlying
3 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Ordinary Shares
DirectShares owned15.75M
Total
15.75M direct15.75M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Ordinary Shares | 15.75M | Direct |
| Total | 15.75M | 15.75M direct |
Derivative Holdings3
Stock Option (Right to Buy)
DirectUnderlying security
Ordinary Shares
Underlying shares
13.50M
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Ordinary Shares
Underlying shares
3.75M
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Ordinary Shares
Underlying shares
1.50M
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Total
Underlying
18.75M
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Ordinary Shares | — | — | 13.50M | N/A | |
| Stock Option (Right to Buy) Direct | Ordinary Shares | — | — | 3.75M | N/A | |
| Stock Option (Right to Buy) Direct | Ordinary Shares | — | — | 1.50M | N/A | |
| Total | 18.75M | 0.00 | ||||